TP53INP1 overexpression in prostate cancer correlates with poor prognostic factors and is predictive of biological cancer relapse

Prostate

Volumn 72, Issue 2, 2012, Pages 117-128

  Giusiano, Sophie ^a,b,c   Garcia, Stéphane ^a   Andrieu, Claudia ^b   Dusetti, Nelson Javier ^b   Bastide, Cyrille ^a,c   Gleave, Martin ^d   Taranger Charpin, Colette ^a   Iovanna, Juan Lucio ^b   Rocchi, Palma ^b  

^a HÔPITAL NORD   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

biological relapse; prostate cancer; quantitative immunohistochemistry; tissue micro arrays; TP53INP1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; MESSENGER RNA; PROTEIN; TUMOR PROTEIN 53 INDUCED NUCLEAR PROTEIN 1; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; APOPTOSIS; ARTICLE; BASAL CELL; CANCER INVASION; CANCER RELAPSE; CELL PROLIFERATION; CELL STRAIN LNCAP; DENSITOMETRY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CARRIER PROTEINS; FLOW CYTOMETRY; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84455172182     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21412     Document Type: Article

References (35)

1. Tomasini R, Samir AA, Vaccaro MI, Pebusque MJ, Dagorn JC, Iovanna JL, Dusetti NJ,. Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death. J Biol Chem 2001; 276: 44185-44192.
2. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, Monden M, Nakamura Y,. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 2001; 8: 85-94. (Pubitemid 32772907)
3. Tomasini R, Samir AA, Pebusque MJ, Calvo EL, Totaro S, Dagorn JC, Dusetti NJ, Iovanna JL,. P53-dependent expression of the stress-induced protein (SIP) Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death. Eur J Cell Biol 2002; 81: 294-301.
4. Tomasini R, Samir AA, Carrier A, Isnardon D, Cecchinelli B, Soddu S, Malissen B, Dagorn JC, Iovanna JL, Dusetti NJ,. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem 2003; 278: 37722-37729. (Pubitemid 37175297)
5. Cano CE, Gommeaux J, Pietri S, Culcasi M, Garcia S, Seux M, Barelier S, Vasseur S, Spoto RP, Pebusque MJ, Dusetti NJ, Iovanna JL, Carrier A,. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Canc Res 2009; 69: 219-226.
6. Jiang PH, Motoo Y, Garcia S, Iovanna JL, Pebusque MJ, Sawabu N,. Down-expression of tumor protein p53-induced nuclear protein 1 in human gastric cancer. World J Gastroenterol 2006; 12: 691-696. (Pubitemid 43380749)
7. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, Gleave M, Dagorn JC, Iovanna JL, Carrier A, Pebusque MJ, Dusetti NJ,. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104: 16170-16175. (Pubitemid 350099380)
8. Gommeaux J, Cano C, Garcia S, Gironella M, Pietri S, Culcasi M, Pebusque MJ, Malissen B, Dusetti N, Iovanna J, Carrier A,. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol Cell Biol 2007; 27: 2215-2228. (Pubitemid 46418477)
9. Taieb D, Giusiano S, Sebag F, Marcy M, de Micco C, Palazzo FF, Dusetti NJ, Iovanna JL, Henry JF, Garcia S, Taranger-Charpin C,. Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: A molecular guide to the optimal extent of surgery? World J Surg 34: 830-835.
10. Gronberg H,. Prostate cancer epidemiology. Lancet 2003; 361: 859-864. (Pubitemid 36331852)
11. De Marzo AM, Marchi VL, Epstein JI, Nelson WG,. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-1992.
12. Putzi MJ, De Marzo AM,. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000; 56: 828-832.
13. Nelson WG, De Marzo AM, Isaacs WB,. Prostate cancer. N Engl J Med 2003; 349: 366-381. (Pubitemid 36886244)
14. Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC,. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Canc Res 1997; 3: 1389-1397. (Pubitemid 27362401)
15. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP,. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166: 2185-2188. (Pubitemid 33065253)
16. Stamey TA, McNeal JE, Freiha FS, Redwine E,. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988; 139: 1235-1241.
17. Altman DG, Lausen B, Sauerbrei W, Schumacher M,. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-835. (Pubitemid 2100935)
18. Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C, Horschowski N, Piana L,. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994; 86: 1539-1545. (Pubitemid 24330219)
19. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, Lavaut MN, Allasia C,. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 1997; 28: 289-296. (Pubitemid 27106080)
20. Charpin C, Garcia S, Bouvier C, Martini F, Andrac L, Bonnier P, Lavaut MN, Allasia C,. CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: Correlation with patient follow-up. Am J Clin Pathol 1997; 107: 534-541. (Pubitemid 27183985)
21. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, Lavaut MN, Allasia C,. Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays. J Pathol 1998; 184: 401-407. (Pubitemid 28179899)
22. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, Lavaut MN, Allasia C,. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: Correlation with 10-year follow-up. J Clin Oncol 1998; 16: 2025-2031. (Pubitemid 28265036)
23. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C,. Long-term prognostic significance of neoangiogenesis in breast carcinomas: Comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol 2004; 35: 176-183. (Pubitemid 38240899)
24. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C,. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. Int J Canc 2005; 116: 734-739. (Pubitemid 41099705)
25. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C,. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 2007; 38: 830-841. (Pubitemid 46726507)
26. Charpin C, Giusiano S, Secq V, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S,. Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas. Int J Oncol 2009; 34: 983-993.
27. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S,. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Canc 2009; 124: 2124-2134.
28. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J,. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Canc Res 1999; 5: 2891-2898. (Pubitemid 29493968)
29. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M,. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Canc Res 2004; 64: 6595-6602. (Pubitemid 39297919)
30. Tomasini R, Seux M, Nowak J, Bontemps C, Carrier A, Dagorn JC, Pebusque MJ, Iovanna JL, Dusetti NJ,. TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 2005; 24: 8093-8104. (Pubitemid 41759809)
31. Haverkamp J, Charbonneau B, Ratliff TL,. Prostate inflammation and its potential impact on prostate cancer: A current review. J Cell Biochem 2008; 103: 1344-1353. (Pubitemid 351490705)
32. Culig Z, Steiner H, Bartsch G, Hobisch A,. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005; 95: 497-505. (Pubitemid 41420180)
33. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB,. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6-S11; discussion S11-12.
34. Michalaki V, Syrigos K, Charles P, Waxman J,. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Canc 2004; 90: 2312-2316. (Pubitemid 38961893)
35. Nowak J, Tomasini R, Mattei MG, Azizi Samir LA, Dagorn JC, Dusetti N, Iovanna JL, Pebusque MJ,. Assignment of tumor protein p53 induced nuclear protein 1 (TP53INP1) gene to human chromosome band 8q22 by in situ hybridization. Cytogenet Genome Res 2002; 97: 140E.